Key result
Long-term systemic chemotherapy combined with local radiation resulted in complete remission and no recurrence for 49 months in a 32-year-old man with metastatic prostate rhabdomyosarcoma.
Why the study?
Does long-term chemotherapy with local radiation prevent recurrence in adult metastatic rhabdomyosarcoma of the prostate?
Case Report (n=1)
No
Does long-term chemotherapy with local radiation prevent recurrence in adult metastatic rhabdomyosarcoma of the prostate?
Long-term chemotherapy combined with local radiation can lead to prolonged recurrence-free survival in adult-onset metastatic rhabdomyosarcoma of the prostate.
Answers are grounded in this paper and cite their sources.
Alerts clinicians to rhabdomyosarcoma in young men with prostatic masses; leaves open optimal adult regimens beyond IRS protocols.
A 32-year-old man visited our hospital due to urinary retention. Prostate-specific antigen was 13.7 ng/mL. Imaging examinations showed a large prostatic tumor and lung and internal iliac lymph node metastases. Transrectal biopsy confirmed embryonal rhabdomyosarcoma of the prostate classified as cT2bN1M1 (stage IV) by the International Rhabdomyosarcoma Study (IRS) Group staging system. Systemic chemotherapy was started according to the IRS III regimen 36, which consisted of 16 weeks of induction chemotherapy with radiation. After 20 weeks, magnetic resonance imaging showed the disappearance of metastases, and the prostate tumor shrunk markedly. Moreover, prostatic re-biopsy showed no viable tumor cells. Maintenance chemotherapy, excluding vincristine because of severe peripheral nerve disorder, was performed for 2 years. There has been no recurrence for 49 months after the termination of maintenance chemotherapy. To the best of our knowledge, this is the longest surviving case of adult-onset metastatic rhabdomyosarcoma of the prostate reported in the literature.
No takes yet. Share an insight, caveat, or question.
Konno et al. (2017) conducted a case report in Adult metastatic rhabdomyosarcoma of the prostate (n=1). Systemic chemotherapy (IRS III regimen 36) with local radiation was evaluated on Recurrence and survival. Long-term systemic chemotherapy combined with local radiation resulted in complete remission and no recurrence for 49 months in a 32-year-old man with metastatic prostate rhabdomyosarcoma.
Synapse has enriched 10 related papers. Consider them for comparative context: